Immunogen, Inc.
IMGN
Market Cap$0
Close$
$33.47
7.2% upside
Current Fair Value
7.2% upsideUndervalued by 7.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-533,422,000.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.28 |
| Beta | 0.0 |
| Outstanding Shares | 266,264,274 |
| Avg 30 Day Volume | 0 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | -0.0 |
| Price to Sales | 31.23 |
| Price to Book Ratio | 15.62 |
| Enterprise Value to Revenue | -1.85 |
| Enterprise Value to EBIT | 6.65 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | -0.14 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
ESG Score
No data
About Immunogen, Inc.
CEO: Mark Enyedy